The Rising Incidences of CVDs are Propelling the Growth of the Checkpoint Inhibitor Refractory Cancers Market in the APAC Region!
- Himanshu Patni
- November 18, 2023
- HEALTHCARE, NEWS
- Checkpoint Inhibitor Refractory Cancer Market, Checkpoint Inhibitor Refractory Cancer Market Share, Checkpoint Inhibitor Refractory Cancer Market Size, Checkpoint Inhibitor Refractory Cancer Market Trends
- 0 Comments
The Asia Pacific Checkpoint Inhibitor Refractory Cancer market is a rapidly growing market for cancer treatment, and it is expected to provide new and effective treatment options for patients with cancer that have failed to respond to other treatments. The market is driven by the growing prevalence of cancer in the region, as well as the increasing awareness and understanding of the benefits of immunotherapy. The market is also being fueled by the growing use of combination therapies, which involve the use of multiple cancer treatments in combination to improve treatment outcomes. For instance, The Chinese People’s Liberation Army General Hospital is conducting a phase I trial of GSL synthetase inhibitors alone or in combination with immune checkpoint inhibitors in the treatment of patients with advanced relapsed or refractory hematologic malignancies and previously treated solid tumors.
Access sample report (including graphs, charts, and figures) – https://univdatos.com/get-a-free-sample-form-php/?product_id=45804
Further, the Asia-Pacific Checkpoint Inhibitor Refractory Cancers Market is expected to grow at a strong CAGR of 12% during the forecast period (2023-2030). The increasing healthcare expenditure in the region is the major reason for the market growth of Checkpoint Inhibitor Refractory Cancers in the Asia-Pacific.
FIG. 1 APAC Checkpoint Inhibitor Refractory Cancers Market Revenue (2020-2030)- USD Mn
Based on type, the market is segmented into PD-1 inhibitor, PD-L1 inhibitor, and others. As per our analysis, the PD-1 inhibitor segment held a significant share in 2022. The growing use of combination therapies, involving the use of multiple cancer treatments in combination to improve treatment outcomes is the important reason for the considerable share of the segment. PD-1 inhibitors are often used in combination with other immunotherapies, such as CTLA-4 inhibitors and immune checkpoint agonists, to enhance their effectiveness.
Based on the application, the market is segmented into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The Hodgkin lymphoma segment is expected to grow with a higher CAGR in the checkpoint inhibitor refractory cancer market during the forecast period. The increasing incidences of Hodgkin lymphoma are the major driving factor for the fast growth of the anesthesia segment. For instance, according to Cancer.Net, in 2020, 3,087 people were diagnosed with Hodgkin lymphoma in 2020 globally.
For a detailed analysis of Global Checkpoint Inhibitor Refractory Cancers Market browse through – https://univdatos.com/report/checkpoint-inhibitor-refractory-cancer-market/
Global Checkpoint Inhibitor Refractory Cancers Market Segmentation
Market Insight, by Type
· PD-1 Inhibitor
· PD-L1 Inhibitor
· Others
Market Insight, by Application
· Lung Cancer
· Bladder Cancer
· Melanoma
· Hodgkin Lymphoma
· Others
Market Insight, by Region
· North America
o U.S.
o Canada
o Rest of North America
· Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
· APAC
o China
o Japan
o India
o Rest of APAC
· Rest of the World
Top Company Profiles
· Bristol-Myers Squibb Company
· AstraZeneca
· Merck KGaA
· F. Hoffmann-La Roche Ltd
· Regeneron Pharmaceuticals Inc
· Pfizer Inc
· Janssen Global Services, LLC
· 4SC AG
· Mirati Therapeutics, Inc.
· Ascentage Pharma